These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 15800950)
1. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Koshkina NV; Kleinerman ES Int J Cancer; 2005 Sep; 116(3):458-63. PubMed ID: 15800950 [TBL] [Abstract][Full Text] [Related]
2. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. Gordon N; Kleinerman ES J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):189-96. PubMed ID: 20528149 [TBL] [Abstract][Full Text] [Related]
3. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases. Koshkina N; Yang Y; Kleinerman ES Adv Exp Med Biol; 2020; 1258():177-187. PubMed ID: 32767242 [TBL] [Abstract][Full Text] [Related]
4. Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases. Huang G; Nishimoto K; Yang Y; Kleinerman ES Adv Exp Med Biol; 2014; 804():203-17. PubMed ID: 24924176 [TBL] [Abstract][Full Text] [Related]
5. Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. Rodriguez CO; Crabbs TA; Wilson DW; Cannan VA; Skorupski KA; Gordon N; Koshkina N; Kleinerman E; Anderson PM J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):197-206. PubMed ID: 19803732 [TBL] [Abstract][Full Text] [Related]
6. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Gordon N; Koshkina NV; Jia SF; Khanna C; Mendoza A; Worth LL; Kleinerman ES Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4503-10. PubMed ID: 17671136 [TBL] [Abstract][Full Text] [Related]
7. Autophagy in osteosarcoma. O'Farrill JS; Gordon N Adv Exp Med Biol; 2014; 804():147-60. PubMed ID: 24924173 [TBL] [Abstract][Full Text] [Related]
8. Eradication of osteosarcoma lung metastasis using intranasal gemcitabine. Jia SF; Worth LL; Turan M; Duan Xp XP; Kleinerman ES Anticancer Drugs; 2002 Feb; 13(2):155-61. PubMed ID: 11901308 [TBL] [Abstract][Full Text] [Related]
9. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Gordon N; Kleinerman ES Cancer Treat Res; 2009; 152():497-508. PubMed ID: 20213411 [TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Rao-Bindal K; Koshkina NV; Stewart J; Kleinerman ES Curr Cancer Drug Targets; 2013 May; 13(4):411-22. PubMed ID: 23410027 [TBL] [Abstract][Full Text] [Related]
12. Toxicity and efficacy of isolated lung perfusion with gemcitabine in a rat model of pulmonary metastases. Van Putte BP; Hendriks JM; Romijn S; De Greef K; Van Schil PE Thorac Cardiovasc Surg; 2006 Mar; 54(2):129-33. PubMed ID: 16541356 [TBL] [Abstract][Full Text] [Related]
13. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Koshkina NV; Kleinerman ES; Waidrep C; Jia SF; Worth LL; Gilbert BE; Knight V Clin Cancer Res; 2000 Jul; 6(7):2876-80. PubMed ID: 10914737 [TBL] [Abstract][Full Text] [Related]
14. Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Koshkina NV; Rao-Bindal K; Kleinerman ES Cancer; 2011 Aug; 117(15):3457-67. PubMed ID: 21287529 [TBL] [Abstract][Full Text] [Related]
15. Isolated lung perfusion with gemcitabine in a rat: pharmacokinetics and survival. Van Putte BP; Hendriks JM; Romijn S; Pauwels B; Friedel G; Guetens G; De Bruijn EA; Van Schil PE J Surg Res; 2003 Feb; 109(2):118-22. PubMed ID: 12643852 [TBL] [Abstract][Full Text] [Related]
16. VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. Jia SF; Guan H; Duan X; Kleinerman ES J Exp Ther Oncol; 2008; 7(2):89-97. PubMed ID: 18771083 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics after pulmonary artery perfusion with gemcitabine. Van Putte BP; Hendriks JM; Romijn S; Pauwels B; De Boeck G; Guetens G; De Bruijn E; Van Schil PE Ann Thorac Surg; 2003 Oct; 76(4):1036-40; discussion 1040. PubMed ID: 14529980 [TBL] [Abstract][Full Text] [Related]
18. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Koshkina NV; Khanna C; Mendoza A; Guan H; DeLauter L; Kleinerman ES Mol Cancer Res; 2007 Oct; 5(10):991-9. PubMed ID: 17951400 [TBL] [Abstract][Full Text] [Related]
19. Using canine osteosarcoma as a model to assess efficacy of novel therapies: can old dogs teach us new tricks? Rodriguez CO Adv Exp Med Biol; 2014; 804():237-56. PubMed ID: 24924178 [TBL] [Abstract][Full Text] [Related]
20. 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Knight V; Kleinerman ES; Waldrep JC; Giovanella BC; Gilbert BE; Koshkina NV Ann N Y Acad Sci; 2000; 922():151-63. PubMed ID: 11193890 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]